FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999824908> ?p ?o ?g. }

• W1999824908 endingPage "AB271" @default.
• W1999824908 startingPage "AB271" @default.
• W1999824908 abstract "RationaleAttempt to demonstrate nasal fluticasone propionate 200 μg daily (FP200QD) for 14 days is superior to placebo in relieving ocular symptoms.MethodsThis was a randomized, double-blind, parallel group, multicenter study comparing FP200QD with placebo in patients (n = 626, age 12 to 79 years) with seasonal allergic rhinitis. The primary endpoint was change from baseline in patient-rated reflective Total Ocular Symptoms Score (rTOSS). Secondary endpoints included change from baseline in the am and pm rTOSS, end-of-treatment assessment of response, and daily activities impact. Primary analysis was analysis of covariance (linear fixed-effects mode).ResultsFP200QD was more efficacious in ocular symptoms relief than placebo utilizing primary endpoint (difference = -0.36, p = 0.0024). It improved am and pm rTOSS vs placebo (AM: difference = -0.33, p = 0.0057; PM: difference = -0.41, p = 0.0009). More patients on FP200QD reported overall improvement at end of treatment (177 vs 146 in placebo, p = 0.0118). FP200QD significantly improved daily activities as measured by MiniRQLQ (p<0.0001) and was well tolerated.ConclusionsThe study results support that FP200QD relieves ocular symptoms in AR. RationaleAttempt to demonstrate nasal fluticasone propionate 200 μg daily (FP200QD) for 14 days is superior to placebo in relieving ocular symptoms. Attempt to demonstrate nasal fluticasone propionate 200 μg daily (FP200QD) for 14 days is superior to placebo in relieving ocular symptoms. MethodsThis was a randomized, double-blind, parallel group, multicenter study comparing FP200QD with placebo in patients (n = 626, age 12 to 79 years) with seasonal allergic rhinitis. The primary endpoint was change from baseline in patient-rated reflective Total Ocular Symptoms Score (rTOSS). Secondary endpoints included change from baseline in the am and pm rTOSS, end-of-treatment assessment of response, and daily activities impact. Primary analysis was analysis of covariance (linear fixed-effects mode). This was a randomized, double-blind, parallel group, multicenter study comparing FP200QD with placebo in patients (n = 626, age 12 to 79 years) with seasonal allergic rhinitis. The primary endpoint was change from baseline in patient-rated reflective Total Ocular Symptoms Score (rTOSS). Secondary endpoints included change from baseline in the am and pm rTOSS, end-of-treatment assessment of response, and daily activities impact. Primary analysis was analysis of covariance (linear fixed-effects mode). ResultsFP200QD was more efficacious in ocular symptoms relief than placebo utilizing primary endpoint (difference = -0.36, p = 0.0024). It improved am and pm rTOSS vs placebo (AM: difference = -0.33, p = 0.0057; PM: difference = -0.41, p = 0.0009). More patients on FP200QD reported overall improvement at end of treatment (177 vs 146 in placebo, p = 0.0118). FP200QD significantly improved daily activities as measured by MiniRQLQ (p<0.0001) and was well tolerated. FP200QD was more efficacious in ocular symptoms relief than placebo utilizing primary endpoint (difference = -0.36, p = 0.0024). It improved am and pm rTOSS vs placebo (AM: difference = -0.33, p = 0.0057; PM: difference = -0.41, p = 0.0009). More patients on FP200QD reported overall improvement at end of treatment (177 vs 146 in placebo, p = 0.0118). FP200QD significantly improved daily activities as measured by MiniRQLQ (p<0.0001) and was well tolerated. ConclusionsThe study results support that FP200QD relieves ocular symptoms in AR. The study results support that FP200QD relieves ocular symptoms in AR." @default.
• W1999824908 created "2016-06-24" @default.
• W1999824908 creator A5016731920 @default.
• W1999824908 creator A5041694829 @default.
• W1999824908 creator A5045703562 @default.
• W1999824908 creator A5053514017 @default.
• W1999824908 creator A5070229590 @default.
• W1999824908 creator A5075293453 @default.
• W1999824908 creator A5077964491 @default.
• W1999824908 date "2015-02-01" @default.
• W1999824908 modified "2023-09-27" @default.
• W1999824908 title "Efficacy of Fluticasone Propionate Nasal Spray on Ocular Symptoms Relief in Seasonal Allergic Rhinitis" @default.
• W1999824908 doi "https://doi.org/10.1016/j.jaci.2014.12.1828" @default.
• W1999824908 hasPublicationYear "2015" @default.
• W1999824908 type Work @default.
• W1999824908 sameAs 1999824908 @default.
• W1999824908 citedByCount "0" @default.
• W1999824908 crossrefType "journal-article" @default.
• W1999824908 hasAuthorship W1999824908A5016731920 @default.
• W1999824908 hasAuthorship W1999824908A5041694829 @default.
• W1999824908 hasAuthorship W1999824908A5045703562 @default.
• W1999824908 hasAuthorship W1999824908A5053514017 @default.
• W1999824908 hasAuthorship W1999824908A5070229590 @default.
• W1999824908 hasAuthorship W1999824908A5075293453 @default.
• W1999824908 hasAuthorship W1999824908A5077964491 @default.
• W1999824908 hasBestOaLocation W19998249081 @default.
• W1999824908 hasConcept C126322002 @default.
• W1999824908 hasConcept C142724271 @default.
• W1999824908 hasConcept C168563851 @default.
• W1999824908 hasConcept C203092338 @default.
• W1999824908 hasConcept C204787440 @default.
• W1999824908 hasConcept C27081682 @default.
• W1999824908 hasConcept C2776804153 @default.
• W1999824908 hasConcept C2779028295 @default.
• W1999824908 hasConcept C2780973058 @default.
• W1999824908 hasConcept C2781212218 @default.
• W1999824908 hasConcept C42219234 @default.
• W1999824908 hasConcept C71924100 @default.
• W1999824908 hasConcept C85663871 @default.
• W1999824908 hasConcept C98274493 @default.
• W1999824908 hasConceptScore W1999824908C126322002 @default.
• W1999824908 hasConceptScore W1999824908C142724271 @default.
• W1999824908 hasConceptScore W1999824908C168563851 @default.
• W1999824908 hasConceptScore W1999824908C203092338 @default.
• W1999824908 hasConceptScore W1999824908C204787440 @default.
• W1999824908 hasConceptScore W1999824908C27081682 @default.
• W1999824908 hasConceptScore W1999824908C2776804153 @default.
• W1999824908 hasConceptScore W1999824908C2779028295 @default.
• W1999824908 hasConceptScore W1999824908C2780973058 @default.
• W1999824908 hasConceptScore W1999824908C2781212218 @default.
• W1999824908 hasConceptScore W1999824908C42219234 @default.
• W1999824908 hasConceptScore W1999824908C71924100 @default.
• W1999824908 hasConceptScore W1999824908C85663871 @default.
• W1999824908 hasConceptScore W1999824908C98274493 @default.
• W1999824908 hasIssue "2" @default.
• W1999824908 hasLocation W19998249081 @default.
• W1999824908 hasOpenAccess W1999824908 @default.
• W1999824908 hasPrimaryLocation W19998249081 @default.
• W1999824908 hasRelatedWork W1968972903 @default.
• W1999824908 hasRelatedWork W1974634355 @default.
• W1999824908 hasRelatedWork W2020812663 @default.
• W1999824908 hasRelatedWork W2025255009 @default.
• W1999824908 hasRelatedWork W2029154333 @default.
• W1999824908 hasRelatedWork W2069000087 @default.
• W1999824908 hasRelatedWork W2100041918 @default.
• W1999824908 hasRelatedWork W2396847555 @default.
• W1999824908 hasRelatedWork W2408866280 @default.
• W1999824908 hasRelatedWork W2421863737 @default.
• W1999824908 hasVolume "135" @default.
• W1999824908 isParatext "false" @default.
• W1999824908 isRetracted "false" @default.
• W1999824908 magId "1999824908" @default.
• W1999824908 workType "article" @default.